Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals has successfully dosed all 30 patients in the Phase II clinical trial of RECCE® 327 Topical Gel for Acute Bacterial Skin and Skin Structure Infections. Initial results show promising outcomes with either complete cure or significant improvement in infection symptoms. A full analysis of Phase II results is expected in Q1 2025, with plans to initiate additional Australian regulatory trials. The company aims to begin a Phase III study for FDA and TGA approval by H1 2025, showcasing commercial potential in the ASEAN region. The global ABSSSI market presents a substantial opportunity, and Recce's innovative approach addresses the urgent need for broad-spectrum antibiotics amidst rising antimicrobial resistance. Investors are encouraged to inquire further about this milestone and its implications on the company's clinical development journey. More details on this trial can be found at the Australia New Zealand Clinical Trial Registry under the trial ID ACTRN12624000973516.

Recce Pharmaceuticals has successfully dosed all 30 patients in the Phase II clinical trial of RECCE® 327 Topical Gel for Acute Bacterial Skin and Skin Structure Infections. Initial results show promising outcomes with either complete cure or significant improvement in infection symptoms. A full analysis of Phase II results is expected in Q1 2025, with plans to initiate additional Australian regulatory trials. The company aims to begin a Phase III study for FDA and TGA approval by H1 2025, showcasing commercial potential in the ASEAN region. The global ABSSSI market presents a substantial opportunity, and Recce's innovative approach addresses the urgent need for broad-spectrum antibiotics amidst rising antimicrobial resistance. Investors are encouraged to inquire further about this milestone and its implications on the company's clinical development journey. More details on this trial can be found at the Australia New Zealand Clinical Trial Registry under the trial ID ACTRN12624000973516. Please feel free to ask any questions regarding this announcement.

Patient Dosing Complete in Phase II ABSSSI Trial of R327G

Announcement summary